Dermatology
Opinion
A 50-year-old White male presented with a 4- to 5-year history of progressively growing violaceous lesions on his left lower extremity
A 50-year-old presented with a 4- to 5-year history of progressively growing violaceous lesions on his left lower extremity, unresponsive to over-...
Latest News
The earlier baricitinib for severe alopecia areata is started, the better
“If I can keep someone on 4 mg that’s great, but it looks like you can go to a lower dose and do a pretty good job,” Dr. Raj Chovatiya said.
Latest News
Study highlights potential skin cancer risk of UV nail polish dryers
Often referred to as ‘mini tanning beds,’ UV nail polish dryers emit UVA radiation, classified as a carcinogen by the International Agency for...
Latest News
What are the clinical implications of recent skin dysbiosis discoveries?
Activities that can contribute to alterations in skin flora or skin dysbiosis include topical application of steroids, antibiotics, retinoids,...
Latest News
Analysis identifies gaps in CV risk screening of patients with psoriasis
Regional variation in screening rates “is not explained by patient demographics or disease severity.”
Latest News
Frustration over iPLEDGE evident at FDA meeting
Dermatologists argue the iPLEDGE REMS burden is too high for providers and patients. Access problems persist with lockouts and some cite a lack of...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
Latest News
Limited treatment options exist for brittle nail syndrome
“It’s our duty to warn our patients about the evidence for biotin for treating brittle nails, and about this interference on laboratory tests,” Dr...
Latest News
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...
Latest News
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
Delgocitinib is an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway.
Latest News
Air pollution may be causing eczema
There are now more than three times as many eczema cases as there were in the 1970s, and it now affects as many as 20% of children and 10% of...